SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $208,000 | +47.5% | 7,494 | +59.7% | 0.00% | – |
| Q2 2023 | $141,000 | -8.4% | 4,692 | +9.6% | 0.00% | – |
| Q1 2023 | $154,000 | -52.6% | 4,282 | -53.0% | 0.00% | – |
| Q4 2022 | $325,000 | +151.9% | 9,103 | +139.6% | 0.00% | – |
| Q3 2022 | $129,000 | +207.1% | 3,799 | +159.5% | 0.00% | – |
| Q2 2022 | $42,000 | -68.4% | 1,464 | -64.5% | 0.00% | – |
| Q1 2022 | $133,000 | -49.2% | 4,127 | -54.2% | 0.00% | – |
| Q4 2021 | $262,000 | +67.9% | 9,020 | +54.8% | 0.00% | – |
| Q3 2021 | $156,000 | +13.0% | 5,825 | +29.7% | 0.00% | – |
| Q2 2021 | $138,000 | +100.0% | 4,491 | +69.0% | 0.00% | – |
| Q1 2021 | $69,000 | -86.8% | 2,658 | -87.2% | 0.00% | – |
| Q4 2020 | $522,000 | +21.7% | 20,755 | +0.8% | 0.00% | – |
| Q3 2020 | $429,000 | -13.5% | 20,596 | -1.3% | 0.00% | – |
| Q2 2020 | $496,000 | +30.2% | 20,873 | -1.5% | 0.00% | – |
| Q1 2020 | $381,000 | +765.9% | 21,181 | +1024.3% | 0.00% | – |
| Q4 2019 | $44,000 | -34.3% | 1,884 | -23.2% | 0.00% | – |
| Q3 2019 | $67,000 | -92.6% | 2,453 | -91.0% | 0.00% | – |
| Q2 2019 | $901,000 | -6.1% | 27,233 | -0.6% | 0.00% | – |
| Q1 2019 | $960,000 | +13.2% | 27,402 | +7.4% | 0.00% | – |
| Q4 2018 | $848,000 | -35.2% | 25,511 | -1.9% | 0.00% | -100.0% |
| Q3 2018 | $1,308,000 | -25.3% | 25,999 | -11.2% | 0.00% | 0.0% |
| Q2 2018 | $1,752,000 | +57.0% | 29,274 | +20.1% | 0.00% | 0.0% |
| Q1 2018 | $1,116,000 | +17.7% | 24,371 | +2.3% | 0.00% | – |
| Q4 2017 | $948,000 | -9.4% | 23,820 | -8.9% | 0.00% | -100.0% |
| Q3 2017 | $1,046,000 | -91.1% | 26,146 | -90.4% | 0.00% | -83.3% |
| Q2 2017 | $11,699,000 | +1126.3% | 271,451 | +790.8% | 0.01% | +500.0% |
| Q1 2017 | $954,000 | +24.9% | 30,473 | +0.7% | 0.00% | – |
| Q4 2016 | $764,000 | +51.0% | 30,251 | +47.7% | 0.00% | – |
| Q3 2016 | $506,000 | +29.7% | 20,475 | +7.0% | 0.00% | – |
| Q2 2016 | $390,000 | +16.4% | 19,136 | -12.8% | 0.00% | – |
| Q1 2016 | $335,000 | +93.6% | 21,946 | +70.9% | 0.00% | – |
| Q4 2015 | $173,000 | +16.1% | 12,842 | +20.7% | 0.00% | – |
| Q3 2015 | $149,000 | -24.0% | 10,636 | -7.6% | 0.00% | – |
| Q2 2015 | $196,000 | +8.3% | 11,505 | -44.6% | 0.00% | – |
| Q3 2014 | $181,000 | -35.6% | 20,781 | -19.0% | 0.00% | – |
| Q2 2014 | $281,000 | – | 25,668 | +256580.0% | 0.00% | – |
| Q2 2013 | $0 | – | 10 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |